What are the open and close dates of the Senores Pharmaceuticals IPO ?

Senores Pharmaceuticals IPO will be open between 2024-12-20 and 2024-12-24.

What is the allotment date for the Senores Pharmaceuticals IPO ?

Senores Pharmaceuticals IPO allotment date is 2024-12-27. For Senores Pharmaceuticals IPO allotment status check, you can visit the website of the registrar of the IPO.

Who is the registrar of Senores Pharmaceuticals IPO ?

For Senores Pharmaceuticals IPO, the IPO registrar is Link Intime India Private Limited. You can check Senores Pharmaceuticals IPO allotment status on the website of the registrar.

Where is the Senores Pharmaceuticals IPO getting listed?

The shares are proposed to be listed on the BSE and NSE.

When will Senores Pharmaceuticals IPO shares be credited to your demat account?

The Senores Pharmaceuticals IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.

What is the lot size and minimum order quantity of the Senores Pharmaceuticals IPO ?

The Senores Pharmaceuticals IPO lot size is 38 and minimum order quantity is 38.

What is the price band for the Senores Pharmaceuticals IPO ?

Senores Pharmaceuticals IPO has set the price band for its IPO at 391 per equity share with a face value of 10.

50.78x

subscribed

Senores Pharmaceuticals IPO

Pharmaceuticals & Drugs

listed

₹14,136Min. investment

Pre-apply
19 Dec
Bid start
20 Dec
Bid end
24 Dec
Allotment
26 Dec
Release of funds
27 Dec
Demat transfer
27 Dec
Listing
30 Dec

Senores Pharmaceuticals Limited IPO Details

Issue size

₹582Cr

IPO type

Mainboard

RevenueApr 2023 - Mar 2024

₹214.52CrLower than sector avg

Price range

₹372 – ₹391

Growth rate3Y CAGR

289%

Lot size

38 shares

Red Herring Prospectus

Read

SectorPharmaceuticals & Drugs

Price range₹372 – ₹391

IPO type

Regular

Lot size38 shares

Issue size₹582Cr

Red Herring Prospectus

Read

RevenueApr 2023 - Mar 2024

₹214.52CrLower than sector avg

Growth rate3Y CAGR

289%

Checklist

Quality analysis

Revenue growth

Company valuation

Earnings expansion

Risk analysis

Debt to Equity ratio

Promoter holdings

Shares pledged

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Compare

Companies in this sector

Sun Pharmaceutical Industries Ltd

Divi's Laboratories Ltd

Torrent Pharmaceuticals Ltd

Revenue

Higher revenue means strong sales and good market demand

This IPO

₹214.52Cr

This sector

₹1,331.47Cr

Compare with companies

PAT

Higher PAT means strong profitability and efficient cost management

This IPO

₹32.71Cr

This sector

₹193.4Cr

Compare with companies

P/E ratio

Lower ratio usually means stock is undervalued

This IPO

32.02

This sector

60.87

Compare with companies

D/E ratio

Lower ratio usually means fewer liabilities

This IPO

1.07

This sector

0.43

Compare with companies

Objectives

New manufacturing facility

The company will invest ₹107 crore in Havix for a sterile injection facility in Atlanta.

Repayment of loans

The company will use ₹73.48 crore for loan repayment and ₹20.22 crore for Havix's loan repayment.

Working capital requirements

The company will allocate ₹43.26 crore for its working capital and ₹59.48 crore to subsidiaries.

About Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited, established in 2017, is a research-driven company focused on developing and manufacturing a wide range of generic pharmaceutical products. The company operates through two key business models: Marketed products (ANDA products and sourced products) and contract development and manufacturing operations (CDMO). As of September 2024, Senores Pharmaceuticals has received approvals for 19 ANDA (Abbreviated New Drug Application) and has commercialised 21 products from these ANDA approvals. Some of the company’s products also have exclusivity periods in key markets, during which no other company can launch competing versions of the same product for six months.

Senores Pharmaceuticals IPO Subscription Status

Date	QIB	NII	Retail	Total
24-Dec-24	58.86 times (X)	46.32 times (X)	34.27 times (X)	50.78 times (X)

Latest News on Senores Pharmaceuticals IPO

Subscription for the mainboard issue will close on Tuesday, December 24. Shares of Senores Pharmaceuticals are expected to be listed on the BSE and the National Stock Exchange of India (NSE) on December 30. The IPO price band has been fixed at ₹372 to ₹391 per share.

4 min read

Ahmedabad-based Senores Pharmaceuticals will launch its maiden public offer on December 20. The issue, which is a combination of fresh equity sale of Rs 500 crore and an offer for sale (OFS) of 21 lakh shares, will close on December 24. The offer is being made through the book-building process, wherein about 75% is reserved for qualified institutional buyers, 15% for non-institutional investors.

Frequently asked questions

How to invest in the Senores Pharmaceuticals IPO ?

Investors can apply for the Senores Pharmaceuticals IPO through their Demat account via the stock exchange or through their broker.

What is the issue size of Senores Pharmaceuticals IPO ?

The issue size of the Senores Pharmaceuticals IPO is 582 Cr.

What is 'pre-apply' for Senores Pharmaceuticals IPO ?

Pre-applying for an IPO allows you to submit your application before the official subscription period begins.

Which exchanges will Senores Pharmaceuticals IPO shares list on?

The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.